doi: 10.1161/01.CIR.0000111581.15521.F5
(Circulation. 2004;109:150-158.)
© 2004 American Heart Association, Inc.
Review: Current Perspectives |
Manipulating Cardiac Contractility in Heart Failure
Data From Mice and Men
From the Department of Internal Medicine, Division of Cardiology (G.W.D.), University of Cincinnati Medical Center, and Division of Molecular Cardiovascular Biology, Department of Pediatrics (J.D.M.), Children’s Hospital Medical Center, Cincinnati, Ohio.
Correspondence to Jeffery D. Molkentin, PhD, Division of Molecular Cardiovascular Biology, Children’s Hospital Medical Center, 3333 Burnet Ave (MLC7020), Cincinnati, OH 45229-3039. E-mail jeff.molkentin@cchmc.org
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
In the year 1990, cardiovascular disease surpassed infectious diseases as the leading cause of death worldwide, and by the year 2020 it is predicted to be the leading cause of all disability.1,2 In the United States, cardiovascular disease has been estimated to account for 44% of the nation’s mortality and is a leading cause of morbidity.3,4 Heart failure afflicts an estimated 5 million Americans, with 
400 000 new individuals diagnosed each year at an annual cost of more than $20 billion.4–6 The alarming reality behind these statistics is our current lack of an effective therapy to repair or otherwise reverse severe forms of cardiac dysfunction and pathological remodeling associated with heart failure. Typically, heart failure is the final culmination of protracted disease states precipitated by underlying hypertension, ischemic disease and atherosclerosis, valvular insufficiency, viral myocarditis, or mutations in genes encoding sarcomeric proteins.6 Given these diverse etiologies, it is not surprising that the final phenotypic manifestations of heart failure can also vary considerably, although dilated cardiomyopathy is the most common. This syndrome is characterized by a progressive loss in contractility and ejection fraction, ventricular chamber dilatation, ventricular wall thinning, increased peripheral vascular resistance, and dysregulated fluid homeostasis. The predominant therapeutic strategy used over the past two decades for treating such patients has been based in pharmacological manipulation of cardiac contractility.7–9 Initially, positive inotropic agents were used as a means of enhancing cardiac pump function aimed at alleviating congestive symptomology. However, use of positive inotropes is now indicated only as a means
This article has been cited by other articles:
 |
|
 |
|
  Q. Liu, X. Chen, S. M. MacDonnell, E. G. Kranias, J. N. Lorenz, M. Leitges, S. R. Houser, and J. D. Molkentin Protein Kinase C{alpha}, but Not PKC{beta} or PKC{gamma}, Regulates Contractility and Heart Failure Susceptibility: Implications for Ruboxistaurin as a Novel Therapeutic Approach Circ. Res., July 17, 2009; 105(2): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Hanft, F. S. Korte, and K. S. McDonald Cardiac function and modulation of sarcomeric function by length Cardiovasc Res, March 1, 2008; 77(4): 627 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hambleton, A. York, M. A. Sargent, R. A. Kaiser, J. N. Lorenz, J. Robbins, and J. D. Molkentin Inducible and myocyte-specific inhibition of PKC{alpha} enhances cardiac contractility and protects against infarction-induced heart failure Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3768 - H3771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., November 28, 2006; (2006) j.jacc.2006.08.039v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hoshijima, R. Knoll, M. Pashmforoush, and K. R. Chien Reversal of Calcium Cycling Defects in Advanced Heart Failure: Toward Molecular Therapy J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A15 - A23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mitchell, A. Ota, W. Foster, B. Zhang, Z. Fang, S. Patel, S. F. Nelson, S. Horvath, and Y. Wang Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation Physiol Genomics, March 13, 2006; 25(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Manso, L. Elsherif, S.-M. Kang, and R. S. Ross Integrins, membrane-type matrix metalloproteinases and ADAMs: Potential implications for cardiac remodeling Cardiovasc Res, February 15, 2006; 69(3): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shaw and L. A. Kirshenbaum Prime Time for JNK-Mediated Akt Reactivation in Hypoxia-Reoxygenation Circ. Res., January 6, 2006; 98(1): 7 - 9. [Full Text] [PDF]
|
|
|
|
|
|
T. Lawo, M. Borggrefe, C. Butter, G. Hindricks, H. Schmidinger, Y. Mika, D. Burkhoff, C. Pappone, and H. N. Sabbah Electrical Signals Applied During the Absolute Refractory Period: An Investigational Treatment for Advanced Heart Failure in Patients With Normal QRS Duration J. Am. Coll. Cardiol., December 20, 2005; 46(12): 2229 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Berenji, M. H. Drazner, B. A. Rothermel, and J. A. Hill Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H8 - H16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Burkhoff and S. A. Ben-Haim Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2550 - H2556. [Full Text] [PDF]
|
|
|
|
|
|
F. Syed, A. Odley, H. S. Hahn, E. W. Brunskill, R. A. Lynch, Y. Marreez, A. Sanbe, J. Robbins, and G. W. Dorn II Physiological Growth Synergizes With Pathological Genes in Experimental Cardiomyopathy Circ. Res., December 10, 2004; 95(12): 1200 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. He, M. Bellini, J. Xu, A. M. Castleberry, and R. A. Hall Interaction with Cystic Fibrosis Transmembrane Conductance Regulator-associated Ligand (CAL) Inhibits {beta}1-Adrenergic Receptor Surface Expression J. Biol. Chem., November 26, 2004; 279(48): 50190 - 50196. [Abstract] [Full Text] [PDF]
|
|